Agenix antibody in US diagnostic test
Thursday, 17 February, 2005
AGEN Biomedical, a subsidiary of Brisbane-based biotech Agenix (ASX: AGX), is set to receive royalties from a newly launched test developed by US diagnostics company Biosite that uses AGEN's D-Dimer antibody.
Biosite's Triage D-Dimer diagnostic is a point-of-care diagnostic for the assessment and evaluation of patients suspected of having thromboembolic events including pulmonary embolism and deep vein thrombosis. The ELISA-based test measures five biomarkers including D-Dimer, and provides results within 15 minutes. AGEN licensed the D-Dimer antibody and associated IP to Biosite in November 2003.
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
Maternal cannabis use puts kids at risk of behavioural problems
Children exposed to their mother's cannabis use during pregnancy and after birth are three...
Over-the-counter pain relievers may improve concussion recovery
People who take over-the-counter pain relievers after a concussion may recover faster than those...
